Correlation Between Amicus Therapeutics and Bristol Myers

Can any of the company-specific risk be diversified away by investing in both Amicus Therapeutics and Bristol Myers at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amicus Therapeutics and Bristol Myers into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Amicus Therapeutics and Bristol Myers Squibb, you can compare the effects of market volatilities on Amicus Therapeutics and Bristol Myers and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amicus Therapeutics with a short position of Bristol Myers. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amicus Therapeutics and Bristol Myers.

Diversification Opportunities for Amicus Therapeutics and Bristol Myers

-0.48

Correlation Coefficient

Amicus Therapeutics  Bristol Myers

Very good diversification

The 3 months correlation between Amicus and Bristol is -0.48. Overlapping area represents the amount of risk that can be diversified away by holding Amicus Therapeutics and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and Amicus Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amicus Therapeutics are associated (or correlated) with Bristol Myers. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of Amicus Therapeutics i.e., Amicus Therapeutics and Bristol Myers go up and down completely randomly.

Pair Corralation between Amicus Therapeutics and Bristol Myers

Given the investment horizon of 90 days Amicus Therapeutics is expected to under-perform the Bristol Myers. In addition to that, Amicus Therapeutics is 1.08 times more volatile than Bristol Myers Squibb. It trades about -0.1 of its total potential returns per unit of risk. Bristol Myers Squibb is currently generating about 0.09 per unit of volatility. If you would invest  5,545  in Bristol Myers Squibb on December 28, 2024 and sell it today you would earn a total of  457.00  from holding Bristol Myers Squibb or generate 8.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Amicus Therapeutics  vs.  Bristol Myers Squibb

Amicus Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Amicus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Bristol Myers Squibb

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal primary indicators, Bristol Myers may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Amicus Therapeutics and Bristol Myers

The main advantage of trading using opposite Amicus Therapeutics and Bristol Myers positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amicus Therapeutics position performs unexpectedly, Bristol Myers can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will offset losses from the drop in Bristol Myers' long position.

The idea behind Amicus Therapeutics and Bristol Myers Squibb pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.